Key result
The alternative RAAS pathway, including Ang-(1-5) and alamandine, shows cardioprotective properties in experimental models of septic shock, though human randomized trials remain limited.
This review highlights the complex dysregulation of the RAAS axis in septic shock and identifies downstream metabolites like Ang-(1-5) and alamandine as potential biomarkers and therapeutic targets.
RAAS imbalance correlates with poor septic shock outcomes; hypothesis-generating for alternative-axis therapies pending prospective trials.
The renin-angiotensin-aldosterone system (RAAS) undergoes profound dysregulation during septic shock, defined by persistent hypotension requiring vasopressors to maintain mean arterial pressure ≥ 65 mmHg plus lactate > 2 mmol/L, with mortality exceeding 40%. The classical RAAS pathway becomes impaired with elevated renin but paradoxically low angiotensin (Ang) II levels, correlating with poor outcomes. The alternative Ang-converting enzyme 2-Ang-(1-7)-mas receptor axis provides counter-regulatory effects but represents a "double-edged sword" in sepsis. Elevated circulating Ang-converting enzyme 2 paradoxically predicts worse outcomes, possibly through excessive Ang II depletion contributing to vasoplegia. Downstream metabolites including Ang-(1-5) and alamandine show cardioprotective properties in experimental models. Ang-(1-5) may serve as a biomarker reflecting RAAS dysregulation severity. Elevated dipeptidyl peptidase 3 exacerbates dysfunction by degrading Ang II. Experimental Ang-(1-7) infusion prevented septic shock and reduced vasopressor requirements. However, human randomized trials remain limited. Future research should focus on biomarker-guided patient stratification and multicenter trials establishing clinical utility of alternative RAAS modulation.
No takes yet. Share an insight, caveat, or question.
Srinivasan et al. (2026) conducted a review in Septic shock. Alternative RAAS axis (Ang-(1-5) and alamandine) was evaluated. The alternative RAAS pathway, including Ang-(1-5) and alamandine, shows cardioprotective properties in experimental models of septic shock, though human randomized trials remain limited.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: